A method of treating cancer. The method includes introducing an effective amount of an oxidative catalyzing agent including titanium oxide, zinc oxide, zirconium oxide, tungsten oxide or tin oxide into a biological entity, and irradiating the biological entity with a ray. The oxidative catalyzing agent produces hydroxyl or hydrogen peroxide radicals after irradiation with the ray thereon.

Hwu; Yeu-Kuang

Yang; Tsung-Yeh

Liu; Chi-Jen

Wang; Chang-Hai

Methods of treating cancers

The present invention provides a method of separating and purifying Yttrium-90 (Y-90) from Strontium-90 (Sr-90). In addition, a zirconium (Zr) clean-up step for the Y-90 is provided. Uses of the Y-90 purified by the method include cancer research and treatment. Y-90 is particularly useful in cell directed therapy, e.g., where the Y-90 is attached directly or indirectly to a targeting molecule such as an antibody.

IsoRay Medical, Inc.

Method of separating and purifying Yttrium-90 from Strontium-90

Changes in sialylation of cell surface or plasma proteins are often associated with various cancers and other disease conditions. Provided are methods of detecting biomarkers of conditions associated with a change of sialylation status. Sialylated peptides are first isolated from biological and other samples by loading onto titanium dioxide (TiO2) or zirconium dioxide (ZrO2) stationary phase under acidic conditions in a solution comprising at least 20% organic phase and at least about 6.5 mM of substituted aromatic carboxylic acid, or, alternatively, at least about 11 mM short chain, non-aromatic, hydroxylated carboxylic acid. Sialic acid containing proteins can then be eluted from loaded stationary phase material by exposure to an alkaline solution having pH of 9.0 or greater, preferably at least 10.5. Sialylated peptides isolated by the methods provided can then be analysed by mass spectrometry to identify patterns of sialylation across a sialiome (the entire complement of sialic acid containing peptides in a biological sample) and/or to identify proteins in a sample that are sialylated or that show changes in sialylation status between two or more different samples. In preferred embodiments, sialylated peptides from control and patient samples can be differentially isotopically labelled and compared in a single mass sprectrometry experiment. Also provided are specific biomarkers of bladder cancer. The methods for isolating and analysing sialylated proteins can also by applied to phosphorylated proteins.

Syddansk Universitet

Methods for isolation and analysis of sialylated and phosphorylated peptides

Complexes of the general formula Iwherein M denotes tin, titanium, zirconium or hafnium, R.sup.1 denotes hydrogen or a phenyl radical, it being possible for the phenyl radical to be monosubstituted or polysubstituted by fluorine, chlorine, bromine, nitro, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or trifluoromethyl, R.sup.2 denotes methyl or R.sup.1, with the exception of hydrogen, R.sup.3 denotes hydrogen or chlorine, X denotes fluorine, chlorine or bromine, but not fluorine if M denotes zirconium or hafnium, m denotes the number 1 or 0, or, if R.sup.1 denotes hydrogen, the number 1 and n denotes the number 0, or, if M denotes zirconium or hafnium, the number 1 or 0, exhibit a cytostatic activity which is comparable to that of cisplatin and are less toxic than cisplatin. They are suitable for the produduction of medicaments having an anti-neoplastic action.

zirconium/vähk

Methods of treating cancers

Method of separating and purifying Yttrium-90 from Strontium-90

Methods for isolation and analysis of sialylated and phosphorylated peptides

Metal complexes having an antineoplastic action and medicaments containing these complexes

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus